Industry gains concessions as part of Massachusetts doctor-gift regs
This article was originally published in Scrip
Executive Summary
Massachusetts is once again in the spotlight with its proposed regulations governing drug firm payments and pharmaceutical marketing which would be the most stringent in the US. A draft now circulating is acceptable in many respects to the Massachusetts Biotechnology Council (MBC), in that the new rules have been altered to allow pharmaceutical companies to make payments to healthcare providers with no public disclosure "for genuine research projects and clinical trials", but there are still concerns about supporting the mission of biotech in a state with such strict marketing regulations.